Cargando…

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment

Detalles Bibliográficos
Autores principales:	Ascierto, Paolo Antonio, Borgognoni, Lorenzo, Botti, Gerardo, Guida, Michele, Marchetti, Paolo, Mocellin, Simone, Muto, Paolo, Palmieri, Giuseppe, Patuzzo, Roberto, Quaglino, Pietro, Stanganelli, Ignazio, Caracò, Corrado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751610/ https://www.ncbi.nlm.nih.gov/pubmed/31533733 http://dx.doi.org/10.1186/s12967-019-2067-0

Ejemplares similares

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma
por: Colombino, Maria, et al.
Publicado: (2014)

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
por: Mozzillo, Nicola, et al.
Publicado: (2013)

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)
por: Tropea, Saveria, et al.
Publicado: (2022)

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2012)

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy
por: Casula, Milena, et al.
Publicado: (2009)

The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts
por: Stanganelli, Ignazio, et al.
Publicado: (2022)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
por: Casula, Milena, et al.
Publicado: (2019)

Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
por: Mandalà, Mario, et al.
Publicado: (2020)

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach
por: Manca, Antonella, et al.
Publicado: (2019)

Discrepant alterations in main candidate genes among multiple primary melanomas
por: Colombino, Maria, et al.
Publicado: (2014)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30–39]
por: Mandalà, Mario, et al.
Publicado: (2020)

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
por: Palmieri, Giuseppe, et al.
Publicado: (2017)

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls
por: Casula, Milena, et al.
Publicado: (2009)

Resection in the popliteal fossa for metastatic melanoma
por: Marone, Ugo, et al.
Publicado: (2007)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
por: Spada, Francesca, et al.
Publicado: (2022)

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
por: Botti, Gerardo, et al.
Publicado: (2017)

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
por: Ascierto, Paolo A., et al.
Publicado: (2018)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

The role of spectrophotometry in the diagnosis of melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2010)

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience
por: Cariti, Caterina, et al.
Publicado: (2021)

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Genetic alterations in main candidate genes during melanoma progression
por: Sini, Maria Cristina, et al.
Publicado: (2018)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
por: Ascierto, Paolo A., et al.
Publicado: (2018)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
por: Sacco, Alessandra, et al.
Publicado: (2020)

Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2021)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Melanoma: From Research to Treatment
por: Ascierto, Paolo A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0c228d4ci4sq97f0k0sulmlij7